Katie Kelley

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-353-9888
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard College, Boston, MAA.B.05/1997Biochemical Sciences
    University of California Los Angeles, Los Angeles, CAM.D.05/2002School of Medicine
    University of California Los Angeles, Los Angeles, CAResidency05/2005Internal Medicine
    University of California Los Angeles, Los Angeles, CAChief Residency06/2006Internal Medicine
    University of California San Francisco, San Francisco, CAFellowship10/2009Hematology/Oncology

    Collapse Overview 
    Collapse Overview
    Dr. Robin Kate Kelley is a gastrointestinal oncologist who specializes in cancers arising from the liver, including hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), and gallbladder carcinoma. Her research interests include developing clinical trials of new treatments and combination therapies for these cancers, including immunotherapy approaches as well as translational research to identify molecular and genetic biomarkers of response. Dr. Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She then completed a fellowship in hematology and oncology at UCSF.

    Dr. Kelley received an American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009, an ASCO Young Investigator Award in 2010, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award in 2014. She has authored numerous publications about treatments for advanced liver and bile duct cancers. She is involved in many organizations dedicated to improving the outcomes for patients with primary liver cancers, including National Comprehensive Cancer Network (NCCN) guideline panel for Liver Cancers, the National Cancer Institute Hepatobiliary Cancer Task Force, the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board, and the International Liver Cancer Association Education Committee.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 2021 Sep 22. Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. PMID: 34551969.
      View in: PubMed   Mentions:    Fields:    
    2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021 Sep; 9(9). Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. PMID: 34518290.
      View in: PubMed   Mentions:    Fields:    
    3. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. PMID: 34358484.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021 Sep 20; 39(27):2991-3001. Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. PMID: 34292792.
      View in: PubMed   Mentions: 2     Fields:    
    5. Hepatocellular Carcinoma - Origins and Outcomes. N Engl J Med. 2021 07 15; 385(3):280-282. Kelley RK, Greten TF. PMID: 34260842.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021 Jul; 98:102221. El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. PMID: 34029957.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    7. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Med. 2021 05; 10(9):3059-3067. Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK. PMID: 33811482.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 01 21; 7(1):6. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. PMID: 33479224.
      View in: PubMed   Mentions: 66     Fields:    
    9. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020 08; 5(4). Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. PMID: 32847838.
      View in: PubMed   Mentions:
    10. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2020 09 15; 26(18):4795-4804. Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. PMID: 32636319.
      View in: PubMed   Mentions: 4     Fields:    
    11. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist. 2020 12; 25(12):e1825-e1836. Harding JJ, Kelley RK, Tan B, Capanu M, Do GK, Shia J, Chou JF, Ferrer CS, Boussayoud C, Muenkel K, Yarmohammadi H, El Dika I, Khalil DN, Ruiz C, Rodriguez-Lee M, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK. PMID: 32548867.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    12. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol. 2020 Jul; 16(21):1525-1536. Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L. PMID: 32491932.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    13. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. Adv Ther. 2020 06; 37(6):2678-2695. Kelley RK, Mollon P, Blanc JF, Daniele B, Yau T, Cheng AL, Valcheva V, Marteau F, Guerra I, Abou-Alfa GK. PMID: 32424805.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    14. Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer. N Engl J Med. 2020 05 14; 382(20):1953-1955. Kelley RK. PMID: 32402168.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    15. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. PMID: 32416072.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    16. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 10 15; 147(8):2190-2198. Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. PMID: 32359091.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    17. Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma. Clin Liver Dis (Hoboken). 2020 Feb; 15(2):53-58. Huppert LA, Gordan JD, Kelley RK. PMID: 32226615.
      View in: PubMed   Mentions:
    18. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS One. 2020; 15(3):e0222259. Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S. PMID: 32210440.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    19. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value Health. 2020 05; 23(5):551-558. Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA. PMID: 32389219.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020 02; 72(2):353-363. Kelley RK, Bridgewater J, Gores GJ, Zhu AX. PMID: 31954497.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    21. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020 04; 17(4):238-251. Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. PMID: 31900465.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    22. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. PMID: 30058032.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    23. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019 Nov 01; 5(11):1582-1588. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. PMID: 31486832.
      View in: PubMed   Mentions: 28     Fields:    
    24. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019 10 18; 7(1):267. Keenan BP, Fong L, Kelley RK. PMID: 31627733.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    25. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer. 2019 Dec 15; 125(24):4426-4434. Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK. PMID: 31454426.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    26. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019 Aug; 10(4):751-765. Boscoe AN, Rolland C, Kelley RK. PMID: 31392056.
      View in: PubMed   Mentions:
    27. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. PMID: 31363003.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    28. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 2019 08; 39(8):1468-1477. Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G. PMID: 30963691.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    29. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer. 2019 09 15; 125(18):3234-3241. Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK. PMID: 31154669.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    30. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079. Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. PMID: 31109923.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    31. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 2019 06; 248(2):164-178. Joseph NM, Tsokos CG, Umetsu SE, Shain AH, Kelley RK, Onodera C, Bowman S, Talevich E, Ferrell LD, Kakar S, Krings G. PMID: 30690729.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    32. Heterogeneous Uptake of 18F-FDG and 68Ga-PSMA-11 in Hepatocellular Carcinoma. Clin Nucl Med. 2019 Mar; 44(3):e133-e135. Perez PM, Flavell RR, Kelley RK, Umetsu S, Behr SC. PMID: 30624275.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. Oncologist. 2019 06; 24(6):747-e218. El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK. PMID: 30598500.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    34. Emerging Role for Systemic Therapy in Earlier Stages of HCC. Int J Radiat Oncol Biol Phys. 2018 12 01; 102(5):1407. Kelley RK. PMID: 31014785.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Cabozantinib in Hepatocellular Carcinoma. N Engl J Med. 2018 10 04; 379(14):1384-1385. Abou-Alfa GK, Borgman-Hagey AE, Kelley RK. PMID: 30281991.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    36. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 05; 379(1):54-63. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. PMID: 29972759.
      View in: PubMed   Mentions: 451     Fields:    Translation:HumansCTClinical Trials
    37. Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. Oncologist. 2018 09; 23(9):998-1003. Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK. PMID: 29622700.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. PMID: 29182496.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansCTClinical Trials
    39. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 02; 15(2):95-111. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. PMID: 28994423.
      View in: PubMed   Mentions: 247     Fields:    Translation:Humans
    40. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    41. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. PMID: 28340509.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    42. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 07; 22(7):804-810. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. PMID: 28487467.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    43. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 05; 15(5):563-573. Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. PMID: 28476736.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    44. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017 03 01; 28(3):528-534. Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E. PMID: 28426123.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    45. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. PMID: 28188191.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    46. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256. Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. PMID: 28893116.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    47. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. PMID: 28078110.
      View in: PubMed   Mentions:
    48. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. PMID: 28078106.
      View in: PubMed   Mentions:
    49. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122(24):3838-3847. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. PMID: 27622582.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    50. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 05; 23(5):411-8. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. PMID: 27080472.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    51. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    52. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Mar 15; 22(6):1348-55. Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL. PMID: 26490310.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    53. Adjuvant sorafenib for liver cancer: wrong stage, wrong dose. Lancet Oncol. 2015 Oct; 16(13):1279-81. Kelley RK. PMID: 26433814.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    54. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. PMID: 26251290.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    55. A 46-Year-Old Asian Woman With Liver Mass. Semin Oncol. 2015 Oct; 42(5):e67-76. Morris GJ, Covey AM, D'Angelica M, Chang DT, Yen Y, Kelley RK, Greenberg H, Tsioulias G. PMID: 26433558.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Biliary Tract Cancers: Finding Better Ways to Lump and Split. J Clin Oncol. 2015 Aug 20; 33(24):2588-90. Kelley RK, Bardeesy N. PMID: 26195717.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    57. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 01; 121(19):3481-90. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. PMID: 26177599.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    58. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    59. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer. 2015 Jun; 46(2):161-5. Parks AL, McWhirter RM, Evason K, Kelley RK. PMID: 25662892.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    60. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015 Mar 31; 15:206. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. PMID: 25884197.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    61. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw. 2015 Mar; 13(3):311-8. Trosman JR, Weldon CB, Kelley RK, Phillips KA. PMID: 25736008.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    62. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. Anticancer Res. 2014 Dec; 34(12):7357-60. Cinar P, Calkins SM, Venook AP, Kelley RK. PMID: 25503172.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    63. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15; 136(8):1967-75. Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. PMID: 25242168.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    64. Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Aug; 12(8):1152-82. Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H. PMID: 25099447.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    65. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. PMID: 25006153.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    66. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. PMID: 24448917.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    67. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013 Dec; 2(4):33. Subramaniam S, Kelley RK, Venook AP. PMID: 25841912.
      View in: PubMed   Mentions: 30     Fields:    
    68. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    69. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. J Clin Oncol. 2013 Oct 01; 31(28):3483-6. Kelley RK. PMID: 23980088.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    70. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-1907. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    71. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013 Jan; 6(1):3-9. Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, Torbenson MS, Ferrell L, Pawlik TM, Fong Y, O'Reilly EM, Ma J, McGuire J, Vallarapu GP, Griffin A, Stipa F, Capanu M, Dematteo RP, Venook AP, Abou-Alfa GK. PMID: 23505572.
      View in: PubMed   Mentions:
    72. Novel therapeutics in hepatocellular carcinoma: how can we make progress? Am Soc Clin Oncol Educ Book. 2013. Kelley RK, Venook AP. PMID: 23714481.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    73. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. PMID: 21552099.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    74. Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transpl. 2012 May; 18(5):509-13. Kelley RK, Hirose R, Venook AP. PMID: 22389236.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    75. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9. Kelley RK, Atreya C, Venook AP, Febbo PG. PMID: 22393192.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    76. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):354-62. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. PMID: 22083023.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    77. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011 Nov; 9 Suppl 5:S1-32; quiz S33. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. PMID: 22138009.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    78. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw. 2011 Nov; 9(11):1293-302. Kelley RK, Wang G, Venook AP. PMID: 22056657.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    79. Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: a new strategy? J Hepatol. 2012 Jan; 56(1):14-6. Kelley RK, Yao F. PMID: 21872558.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    80. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 2011 Jun; 10(2):73-80. Kelley RK, Venook AP. PMID: 21859557.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    81. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. PMID: 21245436.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):13-25. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. PMID: 21233242.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    83. KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic. PLoS Curr. 2010 Sep 02; 2. Wang G, Kelley RK, Gappnet . PMID: 20877448.
      View in: PubMed   Mentions:
    84. Nonadherence to imatinib during an economic downturn. N Engl J Med. 2010 Aug 05; 363(6):596-8. Kelley RK, Venook AP. PMID: 20818898.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    85. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    86. Drug development in advanced colorectal cancer: challenges and opportunities. Curr Oncol Rep. 2009 May; 11(3):175-85. Kelley R, Venook AP. PMID: 19336009.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    87. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008 Dec 20; 26(36):5845-8. Kelley RK, Venook AP. PMID: 19029408.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    88. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95. Kelley RK, Ko AH. PMID: 19707431.
      View in: PubMed   Mentions:
    Katie's Networks
    Concepts (303)
    Derived automatically from this person's publications.
    _
    Co-Authors (78)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _